The Christie Hospital Tamoxifen Trial - 10 Year Results
Author Information
Author(s): G. Ribeiro, R. Swindell
Primary Institution: The Christie Hospital and Holt Radium Institute
Hypothesis
Does tamoxifen improve overall and disease-free survival in operable breast cancer patients compared to irradiation menopause?
Conclusion
Tamoxifen treatment showed a trend towards better disease-free survival in premenopausal patients, but the results were not statistically significant.
Supporting Evidence
- Tamoxifen treatment resulted in a 93% ten-year survival for premenopausal node-negative patients compared to 82% for those receiving irradiation menopause.
- Overall survival for premenopausal patients was 63% for tamoxifen versus 56% for irradiation menopause, but not statistically significant.
- Postmenopausal patients showed no significant difference in survival between tamoxifen and control groups.
Takeaway
This study looked at women with breast cancer who took a medicine called tamoxifen after surgery. It found that while tamoxifen might help some women live longer without cancer coming back, it didn't help everyone.
Methodology
A randomized clinical trial comparing tamoxifen treatment to irradiation menopause in premenopausal and postmenopausal women with operable breast cancer.
Limitations
The study did not include a control group receiving no treatment, and the follow-up period may not have been long enough to detect significant differences.
Participant Demographics
Patients aged 35-70 years with operable breast carcinoma; 373 premenopausal and 588 postmenopausal women.
Statistical Information
P-Value
P=0.09 for premenopausal node negative patients; P=0.07 for overall disease-free survival.
Want to read the original?
Access the complete publication on the publisher's website